瑞格列奈联合二甲双胍对2型糖尿病的治疗价值

Value of repaglinide combined with metformin in the treatment of type 2 diabetes mellitus

目的研究瑞格列奈联合二甲双胍对2型糖尿病的治疗价值。方法选择我院2014年4月至2015年10月收治的2型糖尿病患者80例,将其随机分为单药组和联合用药组。单药组采取二甲双胍进行治疗,联合用药组采取瑞格列奈联合二甲双胍进行治疗,比较两组患者治疗总有效率、不良反应发生率、用药前和用药10周后患者的血糖水平与体质量、血脂水平、生活质量的差异。结果联合用药组的治疗总有效率高于单药组(P<0.05),且两组患者均无严重不良反应发生(P>0.05);用药前,两组患者血糖水平、体质量无明显差异(P>0.05);用药10周后,联合用药组的血糖水平、体质量改善优于单药组(P<0.05);用药前,两组血脂水平无明显差异(P>0.05);用药10周后,联合用药组的血脂水平优于单药组(P<0.05);用药前,两组生活质量无明显差异(P>0.05);用药10周后,联合用药组的生活质量评分更优(P>0.05)。结论瑞格列奈联合二甲双胍治疗2型糖尿病,可有效控制患者血糖,降低血脂水平,控制体质量增长,提升患者生活质量,且安全性高,值得推广应用。

Objective To study the value of repaglinide combined with metformin in the treatment of type 2 diabetes mellitus. Methods Eighty cases of patients with type 2 diabetes mellitus in our hospital from April 2014 to October 2015 were selected, which were randomly divided into single drug group and combined drug group. The single drug group took metformin treatment, while the combined drug group took repaglinide combined with metformin. The total effective rate, adverse reaction incidence rate, blood glucose level and body weight, blood lipid level and quality of life before medication and after 10 weeks medication between the two groups were compared. Results The total effective rate of the combined drug group was higher than that of the single drug group （P〈0.05）, and there was no serious adverse reaction in the two groups （P 〉0.05）. Before medication, the blood glucose level and body weight of the two groups were not significantly different （P〉0.05）. After 10 weeks medication, the blood glucose level and body weight of the combined drug group were better than those of the single drug group （P〈0.05）. Before medication, there was no significant difference in blood lipid level between the two groups （P〉0.05）. After 10 weeks medication, the blood lipid level of the combined drug group was better than that of the single drug group （P〈0.05）. Before medication, there was no significant difference in quality of life between the two groups （P〉0.05）. After 10 weeks medication, the quality of life of the combined drug group improved significantly than that of the single drug group （P〈0.05）. Conclusion Repaglinide combined with metformin in the treatment of type 2 diabetes mellitus can not only effectively control blood glucose, serum lipid level, body weight growth, but also improve the quality of life of the patients, which has high safety. It is worthy of popularization and application.